BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31351207)

  • 1. The Influence of Distinct Regulatory miRNAs of the p15/p16/RB1/E2F Pathway on the Clinical Progression of Glioblastoma Multiforme.
    Sippl C; Teping F; Ketter R; Braun L; Tremmel L; Schulz-Schaeffer W; Oertel J; Urbschat S
    World Neurosurg; 2019 Dec; 132():e900-e908. PubMed ID: 31351207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
    Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
    Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors.
    Ferreira WA; Araújo MD; Anselmo NP; de Oliveira EH; Brito JR; Burbano RR; Harada ML; Borges Bdo N
    PLoS One; 2015; 10(8):e0137259. PubMed ID: 26317630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells.
    Guo P; Nie Q; Lan J; Ge J; Qiu Y; Mao Q
    Biochem Biophys Res Commun; 2013 Nov; 441(1):186-90. PubMed ID: 24140063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
    Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
    Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
    Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
    Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
    Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
    Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identify signature regulatory network for glioblastoma prognosis by integrative mRNA and miRNA co-expression analysis.
    Bing ZT; Yang GH; Xiong J; Guo L; Yang L
    IET Syst Biol; 2016 Dec; 10(6):244-251. PubMed ID: 27879479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.
    Qiu S; Lin S; Hu D; Feng Y; Tan Y; Peng Y
    J Transl Med; 2013 Jan; 11():10. PubMed ID: 23302469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?
    Christoph S; Alicia S; Fritz T; Vanessa T; Ralf K; Jin KY; Stefan L; Joachim O
    Acta Neurochir (Wien); 2023 Jun; 165(6):1635-1644. PubMed ID: 37083881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma.
    Xiao Y; Ping Y; Fan H; Xu C; Guan J; Zhao H; Li Y; Lv Y; Jin Y; Wang L; Li X
    Neuro Oncol; 2013 Jul; 15(7):818-28. PubMed ID: 23516263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease.
    Candido S; Lupo G; Pennisi M; Basile MS; Anfuso CD; Petralia MC; Gattuso G; Vivarelli S; Spandidos DA; Libra M; Falzone L
    Oncol Rep; 2019 Sep; 42(3):911-922. PubMed ID: 31322245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.
    Chim CS; Wong KY; Loong F; Lam WW; Srivastava G
    Hum Pathol; 2007 Dec; 38(12):1849-57. PubMed ID: 17900658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
    Yerukala Sathipati S; Huang HL; Ho SY
    BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma.
    Sun J; Gong X; Purow B; Zhao Z
    PLoS Comput Biol; 2012; 8(7):e1002488. PubMed ID: 22829753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme.
    Kamiryo T; Tada K; Shiraishi S; Shinojima N; Nakamura H; Kochi M; Kuratsu J; Saya H; Ushio Y
    J Neurosurg; 2002 May; 96(5):815-22. PubMed ID: 12005388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-675 promotes glioma cell proliferation and motility by negatively regulating retinoblastoma 1.
    Zheng Y; Lu X; Xu L; Chen Z; Li Q; Yuan J
    Hum Pathol; 2017 Nov; 69():63-71. PubMed ID: 28970140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
    Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
    Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
    Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
    Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.